Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Chemokine receptor 5 and its ligands in the immune response to murine tuberculosis.

Badewa AP, Quinton LJ, Shellito JE, Mason CM.

Tuberculosis (Edinb). 2005 May;85(3):185-95.

PMID:
15850756
2.

Macrophage inflammatory protein-1.

Menten P, Wuyts A, Van Damme J.

Cytokine Growth Factor Rev. 2002 Dec;13(6):455-81. Review.

PMID:
12401480
3.

Chemokine-induced phosphorylation of CC chemokine receptor 5 (CCR5).

Olbrich H, Proudfoot AE, Oppermann M.

J Leukoc Biol. 1999 Mar;65(3):281-5. Review.

PMID:
10080528
4.

The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection.

Zeremski M, Petrovic LM, Talal AH.

J Viral Hepat. 2007 Oct;14(10):675-87. Review.

PMID:
17875002
5.

Leukocyte recruitment during pulmonary Cryptococcus neoformans infection.

Huffnagle GB, Traynor TR, McDonald RA, Olszewski MA, Lindell DM, Herring AC, Toews GB.

Immunopharmacology. 2000 Jul 25;48(3):231-6. Review.

PMID:
10960662
6.

Macrophage inflammatory protein-1.

Maurer M, von Stebut E.

Int J Biochem Cell Biol. 2004 Oct;36(10):1882-6. Review.

PMID:
15203102
7.

Current perspectives on cytokines for anti-retroviral therapy in AIDS related B-cell lymphomas.

Sharma V.

Curr Drug Targets Infect Disord. 2003 Jun;3(2):137-49. Review.

PMID:
12769791
8.

Features and functions of gamma delta T lymphocytes: focus on chemokines and their receptors.

Kabelitz D, Wesch D.

Crit Rev Immunol. 2003;23(5-6):339-70. Review.

PMID:
15030305
9.

The role of CCR5 chemokine ligands and antibodies to CCR5 coreceptors in preventing HIV infection.

Lehner T.

Trends Immunol. 2002 Jul;23(7):347-51. Review. No abstract available.

PMID:
12103354
10.

Chemokines and tuberculosis.

Algood HM, Chan J, Flynn JL.

Cytokine Growth Factor Rev. 2003 Dec;14(6):467-77. Review.

PMID:
14563349
11.

MIP-1 alpha and myeloma bone disease.

Roodman GD, Choi SJ.

Cancer Treat Res. 2004;118:83-100. Review.

PMID:
15043189
12.

Chemokine receptor CCR5: from AIDS to atherosclerosis.

Jones KL, Maguire JJ, Davenport AP.

Br J Pharmacol. 2011 Apr;162(7):1453-69. doi: 10.1111/j.1476-5381.2010.01147.x. Review.

13.

Macrophage activating properties of the tryptophan catabolite picolinic acid.

Bosco MC, Rapisarda A, Reffo G, Massazza S, Pastorino S, Varesio L.

Adv Exp Med Biol. 2003;527:55-65. Review.

PMID:
15206716
14.

Molecular mechanisms regulating persistent Mycobacterium tuberculosis infection.

Zahrt TC.

Microbes Infect. 2003 Feb;5(2):159-67. Review.

PMID:
12650774
15.

Roles of lipoarabinomannan in the pathogenesis of tuberculosis.

Strohmeier GR, Fenton MJ.

Microbes Infect. 1999 Jul;1(9):709-17. Review.

PMID:
10611748
16.

Revisiting the Rich's formula: an update about granulomas in human tuberculosis.

Coelho Filho JC, Takenami I, Arruda S.

Braz J Infect Dis. 2013 Mar-Apr;17(2):234-8. doi: 10.1016/j.bjid.2013.01.006. Epub 2013 Mar 5. Review.

17.

Floating between the poles of pathology and protection: can we pin down the granuloma in tuberculosis?

Reece ST, Kaufmann SH.

Curr Opin Microbiol. 2012 Feb;15(1):63-70. doi: 10.1016/j.mib.2011.10.006. Epub 2011 Nov 8. Review.

PMID:
22074861
18.

The role of CCR5 in HCV infection.

Coenen M, Nattermann J.

Eur J Med Res. 2010 Mar 30;15(3):97-101. Review.

19.

Macrophages and control of granulomatous inflammation in tuberculosis.

Flynn JL, Chan J, Lin PL.

Mucosal Immunol. 2011 May;4(3):271-8. doi: 10.1038/mi.2011.14. Epub 2011 Mar 23. Review.

20.

The tuberculous granuloma: an unsuccessful host defence mechanism providing a safety shelter for the bacteria?

Silva Miranda M, Breiman A, Allain S, Deknuydt F, Altare F.

Clin Dev Immunol. 2012;2012:139127. doi: 10.1155/2012/139127. Epub 2012 Jul 3. Review.

Supplemental Content

Support Center